NPM1 and acute myeloid leukemia: Moreover, almost all NPM1 missense mutations (9/10, 90.0%) were accompanied with an AML subtype‐defining cytogenetic or molecular abnormality, all of which were in the low‐risk (seven cases) or high‐risk category (two cases) (data not shown).